Floatz Rating
C39/100
Confidence
Indicative
Sponsor
New York Medical College
Modality
Small molecule
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03719105CT.gov Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Aggressive NK-Cell Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Methotrexate (this asset) | New York Medical College | Early P1 | C · 39 |
| Cyclophosphamide | The Affiliated Hospital of Xuzhou Medical University | P2 | B |
| Fludarabine | The Affiliated Hospital of Xuzhou Medical University | P2 | CCC |
| Mesna | St. Jude Children's Research Hospital | P2 | CCC |
| Anti-Human T-Lymphocyte Immunoglobulin, Rabbit | St. Jude Children's Research Hospital | P2 | CCC |
| cd45ra-depleted dli | St. Jude Children's Research Hospital | P2 | CCC |
| Melphalan | St. Jude Children's Research Hospital | P2 | CCC |
| Anti-Cd56 Car T | The Affiliated Hospital of Xuzhou Medical University | P2 | CCC |
| Thiotepa | St. Jude Children's Research Hospital | P2 | CCC |
+12 more in the Aggressive NK-Cell Leukemia cohort
Other indications for Methotrexate
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 77 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 76 |
| Acute Promyelocytic Leukemia | — | P3 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- CyclophosphamideThe Affiliated Hospital of Xuzhou Medical UniversityB
- FludarabineThe Affiliated Hospital of Xuzhou Medical UniversityCCC
- MesnaSt. Jude Children's Research HospitalCCC
- Anti-Human T-Lymphocyte Immunoglobulin, RabbitSt. Jude Children's Research HospitalCCC
- cd45ra-depleted dliSt. Jude Children's Research HospitalCCC
Citation
Floatz Terminal. Methotrexate in Aggressive NK-Cell Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 13, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/methotrexate-aggressive-nk-cell-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →